Re: Heier et al.: Intravitreal combined aflibercept plus antieplatelet-derived growth factor receptor β for neovascular age-related macular degeneration: results of the phase 2 CAPELLA trial (Ophthalmology. 2020;127:211-220) REPLY

被引：0
|
作者：
Brown, David M. [1 ]
机构：
[1] Retina Consultants Houston, 6560 Fannin,Suite 750, Houston, TX 77030 USA
来源：
OPHTHALMOLOGY | 2021年 / 128卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：E70 / E70
页数：1
相关论文
共 18 条
  • [1] Re: Heier et al.: Intravitreal combined aflibercept plus anti-platelet-derived growth factor receptor β for neovascular age-related macular degeneration: results of the phase 2 CAPELLA trial (Ophthalmology. 2020;127:211-220)
    Nelson, Mark
    OPHTHALMOLOGY, 2021, 128 (10) : E69 - E70
  • [2] Intravitreal Combined Aflibercept plus Anti-Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration Results of the Phase 2 CAPELLA Trial
    Heier, Jeffrey S.
    Wykoff, Charles C.
    Waheed, Nadia K.
    Kitchens, John W.
    Patel, Sunil S.
    Vitti, Robert
    Perlee, Lorah
    Chu, Karen W.
    Leal, Sergio
    Asmus, Friedrich
    Son, Vladimir
    Schmelter, Thomas
    Brown, David M.
    OPHTHALMOLOGY, 2020, 127 (02) : 211 - 220
  • [3] Re: Yeung et al.: β-blockers and neovascular age-related macular degeneration (Ophthalmology. 2017;124:409-411) REPLY
    Yeung, Ling
    Huang, Ting-Shuo
    Sun, Chi-Chin
    OPHTHALMOLOGY, 2017, 124 (09) : E71 - E72
  • [4] Re: Owsley et al.: Commentary: Cautionary remarks on linking cognitive impairment to glaucoma and age-related macular degeneration (Ophthalmology. 2020;127:667)
    Freeman, Ellen
    Varin, Melanie
    Kergoat, Marie-Jeanne
    Belleville, Sylvie
    Li, Gisele
    Roy-Gagnon, Marie-Helene
    Moghadaszadeh, Solmaz
    Rousseau, Jacqueline
    OPHTHALMOLOGY, 2020, 127 (05) : E27 - E27
  • [5] Re: Kunimoto et al.: Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study (Ophthalmology. 2020:127:1331-1334)
    Sharma, Ashish
    Kumar, Nilesh
    Parachuri, Nikulaa
    OPHTHALMOLOGY, 2021, 128 (06) : E30 - E30
  • [6] Re: Campochiaro et al.: The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial (Ophthalmology. 2019;126:1141-1154) REPLY
    Campochiaro, Peter A.
    Maass, Katie F.
    Singh, Natasha
    Barteselli, Giulio
    OPHTHALMOLOGY, 2019, 126 (11) : E88 - E89
  • [7] Re: Campochiaro et al.: The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial (Ophthalmology. 2019;126:1141-1154)
    Sharma, Ashish
    Kumar, Nilesh
    Kuppermann, Baruch D.
    Francesco, Bandello
    OPHTHALMOLOGY, 2019, 126 (11) : E87 - E88
  • [8] Re: Bailey et al: Intralesional macular atrophy in anti-vascular endothelial growth factor therapy for age-related macular degeneration in the IVAN trial (Ophthalmology. 2019;126:75-86) REPLY
    Bailey, Clare
    Scott, Lauren J.
    Rogers, Chris A.
    Reeves, Barnaby C.
    Hamill, Barbra
    Peto, Tunde
    Chakravarthy, Usha
    Harding, Simon P.
    OPHTHALMOLOGY, 2019, 126 (09) : E72 - E73
  • [9] Re: Guymer et al.: Subthreshold nanosecond laser intervention in age-related macular degeneration: The LEAD Randomized Controlled Clinical Trial (Ophthalmology. 2019;126:829-838) Reply
    Guymer, Robyn H.
    Wu, Zhichao
    Chen, Fred K.
    Chakravarthy, Usha
    Arnold, Jennifer J.
    Heriot, Wilson J.
    Durkin, Shane R.
    Luu, Chi D.
    OPHTHALMOLOGY, 2019, 126 (12) : E92 - E93
  • [10] Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, et al.: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials (Ophthalmology 2016;123:1751-1761) Reply
    Maguire, Maureen G.
    OPHTHALMOLOGY, 2017, 124 (03) : E33 - E33
12